Éric Raymond
Impact in
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.05%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 135
- Pancreatic and Hepatic Oncology Research 35
- Lung Cancer Research Studies 32
- Colorectal Cancer Treatments and Studies 32
- Cancer Treatment and Pharmacology 30
-
- PI3K/AKT/mTOR signaling in cancer 33
- Co-authors
- Sandrine J. Faivre (164 shared papers)Esteban Cvitkovic (32 shared papers)Stephen G. Chaney (5 shared papers)G. Kroemer (2 shared papers)Jan Michał WOYNAROWSKI (5 shared papers)Annemilaï Tijeras‐Raballand (21 shared papers)Armand D.E. Gramont (26 shared papers)Cindy Neuzillet (17 shared papers)
- Journals
- Annals of Oncology (27 papers)European Journal of Cancer (24 papers)Targeted Oncology (18 papers)Journal of Clinical Oncology (16 papers)Investigational New Drugs (13 papers)
- Partner nations
- FranceUnited StatesSwitzerland
In The Last Decade
Éric Raymond
307 papers receiving 22.7k citations
Éric Raymond's Hit Papers
Peers
Comparison fields: 5 of 163
- Hepatology 2.6k
- Oncology 8.7k
- Cancer Research 2.5k
- Epidemiology 3.9k
- Neurology 1.7k
Countries citing papers authored by Éric Raymond
This map shows the geographic impact of Éric Raymond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Raymond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Raymond more than expected).
Fields of papers citing papers by Éric Raymond
This network shows the impact of papers produced by Éric Raymond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Raymond. The network helps show where Éric Raymond may publish in the future.
Co-authors
The 25 scholars most cited alongside Éric Raymond, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 315 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 1965 |
| 2 | EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer Hit paper breakdown → | 2012 | 1313 |
| 3 | Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer Hit paper breakdown → | 2005 | 996 |
| 4 | Current development of mTOR inhibitors as anticancer agents Hit paper breakdown → | 2006 | 825 |
| 5 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 729 |
| 6 | Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial Hit paper breakdown → | 2013 | 630 |
| 7 | Molecular basis for sunitinib efficacy and future clinical development Hit paper breakdown → | 2007 | 591 |
| 8 | Oxaliplatin: A review of preclinical and clinical studies Hit paper breakdown → | 1998 | 554 |
| 9 | 2005 | 541 | |
| 10 | Targeting the TGFβ pathway for cancer therapy Hit paper breakdown → | 2014 | 505 |
| 11 | Oxaliplatin: mechanism of action and antineoplastic activity. | 1998 | 458 |
| 12 | 2004 | 429 | |
| 13 | ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas Hit paper breakdown → | 2016 | 426 |
| 14 | Cellular and molecular pharmacology of oxaliplatin. | 2002 | 405 |
| 15 | 2008 | 398 | |
| 16 | Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. | 1999 | 340 |
| 17 | 1997 | 323 | |
| 18 | 2003 | 311 | |
| 19 | 2000 | 265 | |
| 20 | 2009 | 240 |
About Éric Raymond
Éric Raymond is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Hepatology and Epidemiology, having authored 315 papers that have together received 23.4k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (44 papers), Pancreatic and Hepatic Oncology Research (35 papers), PI3K/AKT/mTOR signaling in cancer (33 papers), Lung Cancer Research Studies (32 papers), Colorectal Cancer Treatments and Studies (32 papers), Cancer Treatment and Pharmacology (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (22 papers) and Lung Cancer Treatments and Mutations (19 papers). The work is most often cited by research in Hepatology (2.6k citations), Oncology (8.7k citations), Cancer Research (2.5k citations), Epidemiology (3.9k citations) and Neurology (1.7k citations). Éric Raymond has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include Sandrine J. Faivre, Esteban Cvitkovic, Stephen G. Chaney, G. Kroemer, Jan Michał WOYNAROWSKI, Annemilaï Tijeras‐Raballand, Armand D.E. Gramont, Cindy Neuzillet, C. Le Tourneau and Jean‐Pierre Armand. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Targeted Oncology, Journal of Clinical Oncology and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.